Johnson & Johnson announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%, and international sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.
“Johnson & Johnson delivered strong first-quarter results driven by successful new product launches and the continued growth of key products,” said Alex Gorsky, chairman and CEO of Johnson & Johnson. “Our talented colleagues around the world continue to bring meaningful innovations to patients and customers, addressing significant unmet needs. We also advanced our near-term priorities and long-term growth drivers, positioning us well to deliver sustainable results.”
The company’s worldwide consumer division recorded sales of $3.6 billion for the first quarter, which represented a decrease of 3.2% versus the prior year consisting of an operational decrease of 0.6% and a negative impact from currency of 2.6%. Domestic sales decreased 2.9%, reflecting the divestiture of the sanitary protection business that was completed in October 2013. International sales decreased 3.4%, which reflected an operational increase of 0.7% and a negative currency impact of 4.1%.
Positive contributors to operational results were sales of Aveeno and Dabao skin care products; international sales of Listerine oral care products; and U.S. sales of Zyrtec, an over-the-counter allergy treatment.